NEK2 and prostate cancer: However, an experiment based on 19 cell lines, including gastric cancer, leukemia, colorectal cancer, prostate cancer, breast cancer, and liver cancer, found that gastric cancer cell lines were more sensitive to the NEK2 inhibitor MBM-5 [27], suggesting that NEK2 plays a more critical role in gastric cancer progression.